Get to know our clinical trials

Clinical trial to evaluate the safety, pharmacokinetics, and preliminary antitumor activity of englumafusp alfa (ro7227166) in combination with obinutuzumab and Glofitamab after a pretreatment dose of obin.

THE AIM OF THIS STUDY IS TO DETERMINE THE EFFECTS OF ENGLUMAFUSP ALFA ON CANCER WHEN COMBINED WITH GLOFITAMAB AND TO DETERMINE THE OPTIMAL DOSE OF ENGLUMAFUSP ALFA.

Imagen del Dr. Miguel Ángel Canales Albendea, especialista en Hematología y Hemoterapia de la Clínica Universidad de Navarra. El Dr. Canales se dedica preferencialmente al estudio y tratamiento de los linfomas y procesos linfoproliferativos.
Dr. Miguel Ángel Canales Curriculum
Specialist Hematology and Hemotherapy Department
Navarre headquarters
Madrid headquarters
Cancer Center
Hematologic Cancer Area
Status
In recruitment
headquarters
Pamplona/Madrid

Technical Summary

  • PHASE I/II OPEN-LABEL STUDY TO EVALUATE THE SAFETY, PHARMACOKINETICS, AND PRELIMINARY ANTITUMOR ACTIVITY OF ENGLUMAFUSP ALFA (RO7227166, A 4-1BB LIGAND TARGETING CD19) IN COMBINATION WITH OBINUTUZUMAB AND GLOFITAMAB AFTER PRETREATMENT WITH OBINUTUZUMAB IN PATIENTS WITH RELAPSED/REFRACTORY B-CELL NON-HODGKIN LYMPHOMA
  • Code EudraCT: 2019-000416-28
  • Protocol number: BP41072
  • Promoter: Roche Farma, S.A.
  • Molecule/Drug: Ro7227166
  • Link to Clinical Trials

* The trials only admit a limited number of patients and are subject to inclusion and exclusion criteria. The specialist who assesses your case will inform you of the conditions required to participate in the clinical trial.

More information about this clinical trial

Information offered by the Spanish Registry of Clinical Studies

  • Summary
  • Information
  • Calendar
  • Headquarters
  • Drugs
Read more about this clinical trial
Imagen de un icono azul con un fonendoscopio o estetoscopio.

Do you want to participate in this trial?

Request an appointment for our specialists to assess whether you qualify for this clinical trial

I want to make an appointment
Imagen de un icono azul de un registro en el informe médico.

Do you prefer to send us your reports?

If you prefer, you can send us your medical information and our specialists will evaluate your case without the need to come to the Clinica.

I WANT TO REQUEST A SECOND OPINION